Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $1.4 million.

  • Arrowhead Pharmaceuticals' Other Non-Current Assets fell 5423.29% to $1.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 million, marking a year-over-year decrease of 5423.29%. This contributed to the annual value of $1.4 million for FY2025, which is 6900.94% down from last year.
  • Arrowhead Pharmaceuticals' Other Non-Current Assets amounted to $1.4 million in Q4 2025, which was down 5423.29% from $1.4 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Other Non-Current Assets high stood at $4.5 million for Q3 2024, and its period low was $210000.0 during Q4 2022.
  • Its 5-year average for Other Non-Current Assets is $1.2 million, with a median of $274000.0 in 2021.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Other Non-Current Assets skyrocketed by 202380.95% in 2024 and then crashed by 6966.37% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $273000.0 in 2021, then decreased by 23.08% to $210000.0 in 2022, then rose by 10.48% to $232000.0 in 2023, then surged by 1228.88% to $3.1 million in 2024, then plummeted by 54.23% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q4 2025, $1.4 million for Q3 2025, and $1.4 million during Q2 2025.